{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:32:36Z","timestamp":1791829956165,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40261-019-00752-1","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T02:48:22Z","timestamp":1548298102000},"page":"309-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects"],"prefix":"10.1007","volume":"39","author":[{"given":"Mohammed","family":"Bouhajib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7006-9244","authenticated-orcid":false,"given":"Zia","family":"Tayab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"752_CR1","unstructured":"Janssen Biotech, Inc. Highlights of prescribing information. Zytiga\u00ae (abiraterone acetate) tablets. U.S. FDA revised 02\/2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/202379s024lbl.pdf\n                    \n                  . Accessed 1 Mar 2018."},{"key":"752_CR2","unstructured":"Janssen-Cilag International NV. Summary of product characteristics Zytiga 250\u00a0mg tablets. EMA updated: 11\/2017. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002321\/WC500112858.pdf\n                    \n                  . Accessed 30 Mar 2018. Accessed 01 Mar 2018."},{"key":"752_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.1281","author":"CJ Ryan","year":"2010","unstructured":"Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small E. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.24.1281\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"752_CR4","unstructured":"National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management, clinical guideline. 2014. \n                    https:\/\/www.nice.org.uk\/guidance\/CG175?UNLID=\n                    \n                  . Accessed 1 Mar 2018."},{"key":"752_CR5","unstructured":"National Institute for Health and Care Excellence. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. 2016. \n                    https:\/\/www.nice.org.uk\/guidance\/ta259\n                    \n                  . Accessed 1 Mar 2018."},{"key":"752_CR6","unstructured":"United States Department of Health and Human Services, Food and Drug Administration. Draft guidance on abiraterone acetate. 2016. \n                    https:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-drugs-gen\/documents\/document\/ucm333001.pdf\n                    \n                  . Accessed 1 Mar 2018."},{"key":"752_CR7","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. 2010. \n                    https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf\n                    \n                  . Accessed 6 Jan 2019."},{"key":"752_CR8","unstructured":"United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: draft guidance. 2013. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm377465.pdf\n                    \n                  . Accessed 26 Mar 2018."},{"key":"752_CR9","unstructured":"United States Department of Health and Human Services, Food and Drug Administration. Guidance for industry: bioanalytical method validation: draft guidance. 2013. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070107.Pdf\n                    \n                  . Accessed 26 Mar 2018."},{"key":"752_CR10","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation: draft guidance. 2011. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf\n                    \n                  . Accessed 26 Mar 2018."},{"key":"752_CR11","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: clinical safety data management: definitions and standards for expedited reporting: E2A. 1994. \n                    http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2A\/Step4\/E2A_Guideline.pdf\n                    \n                  . Accessed 23 Feb 2018."},{"key":"752_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0403-6","author":"GE Benoist","year":"2016","unstructured":"Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016. \n                    https:\/\/doi.org\/10.1007\/s40262-016-0403-6\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"key":"752_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.06.010","author":"V Martins","year":"2006","unstructured":"Martins V, Asad Y, Wilsher N, Raynaud F. A validated liquid chromatographic\u2013tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma. J Chromatogr B. 2006. \n                    https:\/\/doi.org\/10.1016\/j.jchromb.2006.06.010\n                    \n                  .","journal-title":"J Chromatogr B."},{"key":"752_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s10895-013-1261-3","author":"A Gong","year":"2013","unstructured":"Gong A, Zhu X. \u03b2-Cyclodextrin sensitized spectrofluorimetry for the determination of abiraterone acetate and abiraterone. J Fluoresc. 2013. \n                    https:\/\/doi.org\/10.1007\/s10895-013-1261-3\n                    \n                  .","journal-title":"J Fluoresc"},{"issue":"2","key":"752_CR15","first-page":"23","volume":"2","author":"E Pushpa Latha","year":"2016","unstructured":"Pushpa Latha E, BushraY Sayeda, Navaya Sri O, Juveriya N, Anusha M, Mani Sagar G, Samuel Shine S. A review on analytical methods for estimation of abiraterone acetate. WJPMR. 2016;2(2):23\u20135.","journal-title":"WJPMR"},{"key":"752_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3986","author":"GE Benoist","year":"2017","unstructured":"Benoist GE, van der Meulen E, Lubberman FJE, Gerritsen WR, Smilde TJ, Schalken JA, Beumer JH, Burger DM, van Erp NP. Analytical challenges in quantifying abiraterone with LC\u2013MS\/MS in human plasma. Biomed Chromatogr. 2017. \n                    https:\/\/doi.org\/10.1002\/bmc.3986\n                    \n                  .","journal-title":"Biomed Chromatogr."},{"issue":"6","key":"752_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/bmc.1726","volume":"26","author":"S Gurav","year":"2012","unstructured":"Gurav S, Punde R, Farooqui J, Zainuddin M, Rajagopal S, Mullangi R. Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC\u2013MS\/MS-ESI: application to a pharmacokinetic study. Biomed Chromatogr. 2012;26(6):761\u20138.","journal-title":"Biomed Chromatogr."},{"key":"752_CR18","doi-asserted-by":"publisher","DOI":"10.1039\/C3AY26611G","author":"TA Wani","year":"2013","unstructured":"Wani TA. Highly sensitive ultra-performance liquid chromatography\u2013tandem mass spectrometry method for the determination of abiraterone in human plasma. Anal Methods. 2013. \n                    https:\/\/doi.org\/10.1039\/C3AY26611G\n                    \n                  .","journal-title":"Anal Methods."},{"key":"752_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2015.03.001","author":"T Belleville","year":"2015","unstructured":"Belleville T, No\u00e9 G, Huillard O, Thomas-Schoemann A, Vidal M, Goldwasser F, Alexandre J, Blanchet B. A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. J Chromatogr B. 2015. \n                    https:\/\/doi.org\/10.1016\/j.jchromb.2015.03.001\n                    \n                  .","journal-title":"J Chromatogr B."},{"key":"752_CR20","doi-asserted-by":"publisher","DOI":"10.23893\/1307-2080.APS.05605","author":"S Reddy","year":"2018","unstructured":"Reddy S, Thomas L, Ramanna L, Mukhopadhyay A, Thangam S. Estimation of abiraterone in human plasma by liquid chromatography tandem mass spectrometry. Acta Pharm Sci. 2018. \n                    https:\/\/doi.org\/10.23893\/1307-2080.APS.05605\n                    \n                  .","journal-title":"Acta Pharm Sci"},{"key":"752_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000387","author":"M Nuland van","year":"2017","unstructured":"van Nuland M, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH. Development and validation of an LC\u2013MS\/MS method for the simultaneous quantification of abiraterone, enzalutamide, and their major metabolites in human plasma. Ther Drug Monit. 2017. \n                    https:\/\/doi.org\/10.1097\/FTD.0000000000000387\n                    \n                  .","journal-title":"Ther Drug Monit."},{"key":"752_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1865-3","author":"M Acharya","year":"2012","unstructured":"Acharya M, Bernard A, Gonzalez M, Jiao J, De Vries R, Tran N. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol. 2012. \n                    https:\/\/doi.org\/10.1007\/s00280-012-1865-3\n                    \n                  .","journal-title":"Cancer Chemother Pharmacol."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00752-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T20:36:21Z","timestamp":1579638981000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00752-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00752-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"22 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Pharma Medica Research Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mohammed Bouhajib and\u00a0Zia Tayab are employees of\u00a0Pharma Medica Research Inc. They do not have any\u00a0other conflicts of interest\u00a0to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol and informed consent form were approved by Salus Institutional Review Board (IRB), Texas, USA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study, prior to any activity in the trial.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}